$JANX
Janux Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022024511 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $2.845M $1.813M $1.159M
YoY Change 76.05% 56.43%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.677M $6.098M $3.656M
YoY Change 44.2% 66.79% 766.35%
% of Gross Profit
Research & Development $15.43M $13.74M $8.406M
YoY Change 38.19% 63.42% 907.91%
% of Gross Profit
Depreciation & Amortization $403.0K $249.0K $27.00K
YoY Change 529.69% 822.22% 2600.0%
% of Gross Profit
Operating Expenses $21.11M $13.74M $8.406M
YoY Change 39.75% 63.42% 907.91%
Operating Profit -$18.02M -$10.90M
YoY Change 65.29% 768.07%
Interest Expense $2.201M $1.326M $137.0K
YoY Change 2874.32% 867.88%
% of Operating Profit
Other Income/Expense, Net $1.326M $137.0K
YoY Change 867.88%
Pretax Income -$16.07M -$16.70M -$10.77M
YoY Change 19.75% 55.08% 757.17%
Income Tax
% Of Pretax Income
Net Earnings -$16.07M -$16.70M -$10.77M
YoY Change 19.75% 55.08% 757.17%
Net Earnings / Revenue -564.67% -920.9% -928.9%
Basic Earnings Per Share -$0.40 -$0.26
Diluted Earnings Per Share -$0.39 -$0.40 -$261.7K
COMMON SHARES
Basic Shares Outstanding 41.66M 41.53M 477.4K
Diluted Shares Outstanding 41.53M 41.13M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $327.0M $338.8M $387.5M
YoY Change -12.79% -12.58%
Cash & Equivalents $51.43M $64.75M $39.39M
Short-Term Investments $275.6M $274.0M $348.1M
Other Short-Term Assets $5.423M $5.070M $2.081M
YoY Change 164.02% 143.63%
Inventory
Prepaid Expenses
Receivables $0.00 $500.0K $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $332.4M $344.3M $389.6M
YoY Change -11.82% -11.62%
LONG-TERM ASSETS
Property, Plant & Equipment $7.086M $6.514M $1.118M
YoY Change 401.84% 482.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.390M $1.433M $140.0K
YoY Change 254.59% 923.57%
Total Long-Term Assets $31.57M $31.43M $1.496M
YoY Change 1025.53% 2000.67%
TOTAL ASSETS
Total Short-Term Assets $332.4M $344.3M $389.6M
Total Long-Term Assets $31.57M $31.43M $1.496M
Total Assets $364.0M $375.8M $391.1M
YoY Change -4.16% -3.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.159M $2.866M $3.613M
YoY Change -12.16% -20.68%
Accrued Expenses $8.010M $7.240M $2.030M
YoY Change 111.96% 256.65%
Deferred Revenue $5.406M $5.906M $5.264M
YoY Change 4.71% 12.2%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.51M $16.34M $12.47M
YoY Change 28.99% 30.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $26.76M $27.91M $1.863M
YoY Change 3723.29% 1398.01%
Total Long-Term Liabilities $26.76M $27.91M $1.863M
YoY Change 3723.29% 1398.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.51M $16.34M $12.47M
Total Long-Term Liabilities $26.76M $27.91M $1.863M
Total Liabilities $43.27M $44.24M $14.33M
YoY Change 220.59% 208.66%
SHAREHOLDERS EQUITY
Retained Earnings -$110.5M -$94.40M -$34.00M
YoY Change 133.07% 177.65%
Common Stock $432.7M $428.2M $410.7M
YoY Change 4.53% 4.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $320.7M $331.5M $376.8M
YoY Change
Total Liabilities & Shareholders Equity $364.0M $375.8M $391.1M
YoY Change -4.16% -3.92%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$16.07M -$16.70M -$10.77M
YoY Change 19.75% 55.08% 757.17%
Depreciation, Depletion And Amortization $403.0K $249.0K $27.00K
YoY Change 529.69% 822.22% 2600.0%
Cash From Operating Activities -$11.91M -$13.41M -$5.854M
YoY Change 13.66% 129.14% 440.54%
INVESTING ACTIVITIES
Capital Expenditures $2.056M -$2.520M -$77.00K
YoY Change -275.28% 3172.73%
Acquisitions
YoY Change
Other Investing Activities $452.0K $22.28M -$205.5M
YoY Change -94.68% -110.85%
Cash From Investing Activities -$1.604M $19.76M -$205.5M
YoY Change -121.89% -109.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 191.0K 0.000 -843.0K
YoY Change 16.46% -100.0% 2454.55%
NET CHANGE
Cash From Operating Activities -11.91M -13.41M -5.854M
Cash From Investing Activities -1.604M 19.76M -205.5M
Cash From Financing Activities 191.0K 0.000 -843.0K
Net Change In Cash -13.33M 6.349M -212.2M
YoY Change 345.54% -102.99% 18917.56%
FREE CASH FLOW
Cash From Operating Activities -$11.91M -$13.41M -$5.854M
Capital Expenditures $2.056M -$2.520M -$77.00K
Free Cash Flow -$13.97M -$10.89M -$5.777M
YoY Change 50.08% 88.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001817713
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40475
dei Entity Registrant Name
EntityRegistrantName
Janux Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2289112
dei Entity Address Address Line1
EntityAddressAddressLine1
10955 Vista Sorrento Parkway, Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
751-4493
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
JANX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41663029
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64752000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35582000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
500000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
274008000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
339383000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5070000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2054000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
344330000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
377019000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
816000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
816000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6514000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1412000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22663000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
185000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1433000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
392000
CY2022Q3 us-gaap Assets
Assets
375756000
CY2021Q4 us-gaap Assets
Assets
379824000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2866000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2458000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7240000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3779000
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5906000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5163000
CY2022Q3 janx Unvested Stock Liabilities
UnvestedStockLiabilities
323000
CY2021Q4 janx Unvested Stock Liabilities
UnvestedStockLiabilities
1203000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
16335000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12797000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
194000
CY2022Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3816000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
700000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
24092000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q3 us-gaap Liabilities
Liabilities
44243000
CY2021Q4 us-gaap Liabilities
Liabilities
13497000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41663029
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41622962
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41550704
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41243137
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
42000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
41000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
428153000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
413967000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2277000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-270000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-94405000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47411000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
331513000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
366327000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
375756000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
379824000
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1813000
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1159000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5767000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2021000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13737000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8406000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38007000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15068000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6098000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3656000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16585000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6392000
us-gaap Interest And Other Income
InterestAndOtherIncome
183000
CY2022Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
19835000
CY2021Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
12062000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
54592000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
21460000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18022000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10903000
us-gaap Operating Income Loss
OperatingIncomeLoss
-48825000
us-gaap Operating Income Loss
OperatingIncomeLoss
-19439000
CY2022Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
1326000
CY2021Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
137000
us-gaap Interest And Other Income
InterestAndOtherIncome
1831000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1326000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
137000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1831000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
183000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-16696000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-10766000
us-gaap Profit Loss
ProfitLoss
-46994000
us-gaap Profit Loss
ProfitLoss
-19256000
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-370000
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
7000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-2007000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
24000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-17066000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-10759000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-49001000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-19232000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.10
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41526524
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41526524
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41134102
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41134102
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41431023
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41431023
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17572807
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17572807
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
366327000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
307000
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
881000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12998000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2007000
us-gaap Net Income Loss
NetIncomeLoss
-46994000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
331513000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-14638000
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
202171000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
204137000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20000
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
326000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3966000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
24000
us-gaap Net Income Loss
NetIncomeLoss
-19256000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
376750000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
343814000
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
169000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4596000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-370000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-16696000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
331513000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
384795000
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
148000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2566000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-10766000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
376750000
us-gaap Profit Loss
ProfitLoss
-46994000
us-gaap Profit Loss
ProfitLoss
-19256000
us-gaap Depreciation
Depreciation
438000
us-gaap Depreciation
Depreciation
49000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-3000
us-gaap Share Based Compensation
ShareBasedCompensation
12998000
us-gaap Share Based Compensation
ShareBasedCompensation
3966000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
891000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
114000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
500000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-8000000
janx Prepaid Expenses And Other Current Assets Includes Related Party Amounts
PrepaidExpensesAndOtherCurrentAssetsIncludesRelatedPartyAmounts
-0
janx Prepaid Expenses And Other Current Assets Includes Related Party Amounts
PrepaidExpensesAndOtherCurrentAssetsIncludesRelatedPartyAmounts
-36000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3288000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1832000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
957000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
140000
janx Accounts Payable Includes Related Party Amounts
AccountsPayableIncludesRelatedPartyAmounts
-36000
janx Accounts Payable Includes Related Party Amounts
AccountsPayableIncludesRelatedPartyAmounts
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-517000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2621000
janx Accrued Expenses Includes Related Party Amounts
AccruedExpensesIncludesRelatedPartyAmounts
-16000
janx Accrued Expenses Includes Related Party Amounts
AccruedExpensesIncludesRelatedPartyAmounts
-544000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3151000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1107000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
3859000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-896000
janx Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
-1692000
janx Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
3000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31009000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6495000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4389000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
309000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
386360000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
29170000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
31576000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36398000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
208341000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
370125000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
272600000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
22145000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
59870000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-348289000
janx Proceeds From Exercise Of Vested And Unvested Common Stock Options And Employee Stock Purchase Plan
ProceedsFromExerciseOfVestedAndUnvestedCommonStockOptionsAndEmployeeStockPurchasePlan
309000
janx Proceeds From Exercise Of Vested And Unvested Common Stock Options And Employee Stock Purchase Plan
ProceedsFromExerciseOfVestedAndUnvestedCommonStockOptionsAndEmployeeStockPurchasePlan
1646000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
204167000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
309000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7813000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
65568000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39389000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
202171000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1189000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
853000
janx Vesting Of Restricted Common Stock
VestingOfRestrictedCommonStock
880000
janx Vesting Of Restricted Common Stock
VestingOfRestrictedCommonStock
326000
us-gaap Stock Issued1
StockIssued1
0
us-gaap Stock Issued1
StockIssued1
30000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2007000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
24000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
23078000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
256000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-94400000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s financial statements are prepared in accordance with GAAP. The preparation of the Company’s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to estimates to complete the performance obligations and the estimated transaction price for collaboration revenue, accruals for research and development expenses, stock-based compensation and fair value measurements. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenues and expenses that are not readily apparent from other sources. Although the impact of the COVID-19 pandemic to the Company’s business and operating results presents additional uncertainty, the Company continues to use the best information available to update its accounting estimates. Actual results may differ materially and adversely from these estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
36916000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
274008000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
816000
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
311740000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
25018000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
339383000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
816000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
365217000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64752000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35582000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
816000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
816000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
65568000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36398000
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
276285000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2277000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
274008000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
339653000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
277000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
339383000
CY2022Q3 us-gaap Financing Receivable Accrued Interest Before Allowance For Credit Loss
FinancingReceivableAccruedInterestBeforeAllowanceForCreditLoss
300000
CY2021Q4 us-gaap Financing Receivable Accrued Interest Before Allowance For Credit Loss
FinancingReceivableAccruedInterestBeforeAllowanceForCreditLoss
200000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
270018000
CY2022Q3 janx Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
3990000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
291267000
CY2021Q4 janx Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
48116000
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
39
janx Number Of Available For Sale Debt Securities
NumberOfAvailableForSaleDebtSecurities
41
CY2022Q3 us-gaap Impaired Financing Receivable Related Allowance
ImpairedFinancingReceivableRelatedAllowance
0
CY2021Q4 us-gaap Impaired Financing Receivable Related Allowance
ImpairedFinancingReceivableRelatedAllowance
0
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
266544000
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
2240000
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
7464000
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
37000
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
274008000
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
2277000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentrations of Risk</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in a federally insured financial institution in excess of federally insured limits. The Company has not experienced any losses in such account and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is also subject to credit risk from its accounts receivable. The Company generally does not perform evaluations of customers’ financial condition and generally does not require collateral. As of September 30, 2022, and December 31, 2021, all of the Company’s accounts receivable, if any, relate to a single customer. For the three and nine months ended September 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and September 30, 2021, all of the Company’s revenue related to a single customer.</span>
CY2022Q3 janx Weighted Average Number Of Unvested Shares
WeightedAverageNumberOfUnvestedShares
136505
CY2021Q3 janx Weighted Average Number Of Unvested Shares
WeightedAverageNumberOfUnvestedShares
477408
janx Weighted Average Number Of Unvested Shares
WeightedAverageNumberOfUnvestedShares
213301
janx Weighted Average Number Of Unvested Shares
WeightedAverageNumberOfUnvestedShares
457556
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7716860
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5995318
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7081000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1543000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
567000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
131000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6514000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1412000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1894000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1171000
CY2022Q3 janx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
4737000
CY2021Q4 janx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2130000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
609000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
478000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7240000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3779000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
18000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2760000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3403000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3505000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3611000
CY2022Q3 janx Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
24421000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
37718000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12890000
CY2022Q3 janx Lessee Operating Lease Liability Lease Incentives
LesseeOperatingLeaseLiabilityLeaseIncentives
736000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
24092000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
24092000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y3M18D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
900000
us-gaap Operating Lease Cost
OperatingLeaseCost
1900000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5654663
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.65
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M19D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
62954000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2115965
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
17.48
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
7405
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.17
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
171653
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
14.77
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7591570
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.73
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M19D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
32451000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7591570
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.73
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y8M19D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
32451000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5143113
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.99
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y5M8D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
31110000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.83
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1000000.0
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
47500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q2 janx Percentage Of Number Of Common Stock Shares
PercentageOfNumberOfCommonStockShares
0.01
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
4596000
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2566000
us-gaap Share Based Compensation
ShareBasedCompensation
12998000
us-gaap Share Based Compensation
ShareBasedCompensation
3966000
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
379825
CY2021Q4 janx Unvested Stock Liabilities
UnvestedStockLiabilities
1203000
janx Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedShares
0
janx Unvested Stock Liabilities Early Exercised Shares
UnvestedStockLiabilitiesEarlyExercisedShares
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
267500
janx Unvested Stock Liabilities Vested Shares
UnvestedStockLiabilitiesVestedShares
880000
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
112325
CY2022Q3 janx Unvested Stock Liabilities
UnvestedStockLiabilities
323000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
500000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0

Files In Submission

Name View Source Status
janx-20220930_def.xml Edgar Link unprocessable
0000950170-22-024511-index-headers.html Edgar Link pending
0000950170-22-024511-index.html Edgar Link pending
0000950170-22-024511.txt Edgar Link pending
0000950170-22-024511-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
janx-20220930.htm Edgar Link pending
janx-20220930.xsd Edgar Link pending
janx-ex31_1.htm Edgar Link pending
janx-ex31_2.htm Edgar Link pending
janx-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
janx-20220930_pre.xml Edgar Link unprocessable
janx-20220930_htm.xml Edgar Link completed
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
janx-20220930_lab.xml Edgar Link unprocessable
janx-20220930_cal.xml Edgar Link unprocessable